Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A Novel Treatment Option for Patients ≥12 Years

0 SAR
Checkout

Overview

Discover how Ebglyss (lebrikizumab) delivers rapid skin clearance and itch
relief for patients with moderate-to-severe atopic dermatitis. Learn about
Week 16 efficacy data from the ADvocate 1 and ADvocate 2 trials, early onset
of action as soon as Day 2, and treatment outcomes illustrated through a real
patient case showing dramatic improvement within 2 weeks of starting
lebrikizumab.


This Class for

  • Clinical Pharmacy
  • Pharmacy
  • Physician
  • Resident / Fellow

What I will learn?

  • - Review Week 16 efficacy results of lebrikizumab from AD vocate 1 & amp; 2, including IGA (0,1), EASI 75, EASI 90, and Pruritus NRS outcomes versus placebo.


    -  Recognize the rapid onset of lebrikizumab, with itch improvement from Day 2 and skin clearance from Weeks 2-4.


    - Identify patients who may benefit from lebrikizumab, including those with persistent or comorbid atopic dermatitis despite prior systemic therapy.


    -Apply clinical trial and real-world evidence to assess baseline disease severity and evaluate early treatment response in a patient case.

    -Understand the key & quot ; Start Strong & quot ; message: lebrikizumab delivers rapid, meaningful
    improvements in itch and skin clearance after initiation.

     

    Disclaimer

    This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
    (This information/content is intended to Health Care Providers only)

    For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com

    24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

    For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com

    For further information, please contact:

    Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com

    PP-LK-SA-0263


Related Classes